Literature DB >> 23391172

Prolonged overall survival after pulmonary metastasectomy in patients with breast cancer.

Georgios Meimarakis1, Dominik Rüttinger, Joachim Stemmler, Alexander Crispin, Rolf Weidenhagen, Martin Angele, Jan Fertmann, Rudolf A Hatz, Hauke Winter.   

Abstract

BACKGROUND: We investigated whether overall survival (OS) in patients with primary breast cancer (BC) is prolonged by pulmonary metastasectomy and which prognostic criteria may facilitate the decision in favor of thoracic surgical intervention.
METHODS: We assessed the median OS of 81 women after resection of pulmonary primary BC metastases by means of Kaplan-Meier estimators. Statistical interferences regarding prognostic factors were based on univariate log-rank tests and multivariate Cox proportional hazards regression. Matched patients who had not undergone resection from the Munich Tumor Registry served as controls.
RESULTS: Between 1982 and 2007, 81 patients were recruited prospectively. In 81.5% of the patients R0 resection was achieved, which was associated with significantly longer median OS than occurred after R1 or R2 resection (103.4 months versus 23.6 months versus 20.2 months, respectively; p<0.001). Multivariate analysis revealed R0 resection, number (n≥2), size (≥3 cm), and estrogen receptor (ER) and/or progesterone receptor (PR) positivity of metastases as independent prognostic factors for long-term survival. Presence of metastases in mediastinal and hilar lymph nodes correlated with decreased survival only in the univariate analysis (32.1 versus 103.4 months; p=0.095). Matched pair analysis confirmed that pulmonary metastasectomy significantly improved survival.
CONCLUSIONS: OS in patients with isolated pulmonary primary BC metastasis is prolonged by metastasectomy. Patients with multiple pulmonary lesions or metastases with negative hormone receptor (HR) status are at greater risk of disease relapse and should be followed closely. Moreover, additive treatment tailored to the biological subtype defined by HR expression should be considered for this group.
Copyright © 2013 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23391172     DOI: 10.1016/j.athoracsur.2012.11.043

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  11 in total

1.  Initial Surgery and Survival in Stage IV Breast Cancer in the United States, 1988-2011.

Authors:  Alexandra Thomas; Seema A Khan; Elizabeth A Chrischilles; Mary C Schroeder
Journal:  JAMA Surg       Date:  2016-05-01       Impact factor: 14.766

2.  Outcomes of Hybrid Video Assisted Thoracoscopic Surgery for Pulmonary Metastasectomy.

Authors:  Ali Raza; Kazuaki Takabe; Luke G Wolfe; C Gregory Lockhart; Roger H Kim
Journal:  J Surg Sci       Date:  2014-12

3.  Prognostic factors for resection of isolated pulmonary metastases in breast cancer patients: a systematic review and meta-analysis.

Authors:  Jun Fan; Dali Chen; Heng Du; Cheng Shen; Guowei Che
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

Review 4.  Oligometastatic breast cancer: a shift from palliative to potentially curative treatment?

Authors:  Simona Di Lascio; Olivia Pagani
Journal:  Breast Care (Basel)       Date:  2014-02       Impact factor: 2.860

Review 5.  [Rationale of thoracic lymph node dissection in pulmonary metastasectomy].

Authors:  S Sponholz; M Schirren; J Schirren
Journal:  Chirurg       Date:  2019-12       Impact factor: 0.955

6.  Lung Metastasectomy for Pulmonary Metastatic Breast Carcinoma.

Authors:  Sascha Macherey; Peter Mallmann; Wolfram Malter; Fabian Doerr; Matthias Heldwein; Thorsten Wahlers; Khosro Hekmat
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-06-28       Impact factor: 2.915

Review 7.  Oligometastasis and oligo-recurrence: more than a mirage.

Authors:  Fang Huang; Gang Wu; Kunyu Yang
Journal:  Radiat Oncol       Date:  2014-10-31       Impact factor: 3.481

8.  Pulmonary metastasectomy for pulmonary metastasis of breast cancer has a limited prognostic impact: a multi-institutional retrospective analysis.

Authors:  Makoto Endoh; Satoshi Shiono; Yoshikane Yamauchi; Mingyon Mun; Norihiko Ikeda; Hiroshi Hashimoto; Hirotoshi Horio; Hisao Asamura; Ichiro Yoshino; Haruhisa Matsuguma; Jun Nakajima; Takahiko Oyama; Yasushi Shintani; Mitsuo Nakayama; Noriyuki Matsutani; Masafumi Kawamura
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

9.  A Novel Staging System for De Novo Metastatic Breast Cancer Refines Prognostic Estimates.

Authors:  Jennifer K Plichta; Samantha M Thomas; Amanda R Sergesketter; Rachel A Greenup; Laura H Rosenberger; Oluwadamilola M Fayanju; Gretchen Kimmick; Jeremy Force; Terry Hyslop; E Shelley Hwang
Journal:  Ann Surg       Date:  2022-04-01       Impact factor: 13.787

Review 10.  Cure in metastatic breast cancer.

Authors:  Theresa Westphal; Simon Peter Gampenrieder; Gabriel Rinnerthaler; Richard Greil
Journal:  Memo       Date:  2018-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.